Study Shows Prolaris Could Save Healthcare System $6B Over 10 Yrs.
December 02, 2014 at 07:03 AM EST
Myriad Genetics, Inc. (Nasdaq: MYGN) today announced that clinical data from three studies with Prolaris in prostate cancer patients ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.